COX-2: A target for prevention and treatment of esophageal cancer

Journal of Surgical Research

Volumn 117, Issue 1, 2004, Pages 114-120

  Altorki, Nasser ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; TAXANE DERIVATIVE; TILMACOXIB;

ANGIOGENESIS; APOPTOSIS; B LYMPHOCYTE; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ESOPHAGUS CANCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; XENOBIOTIC METABOLISM;

EID: 1542268360     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2003.12.005     Document Type: Article

References (64)

1. Stewart B.W., Kleihues P. World Cancer Report. 2003;IARC Press, Lyon, France.
2. Thun M.J., Namboodiri M.M., Calle E.E., Flanders W.D., Heath C.W. Jr. Aspirin use and risk of fatal cancer. Cancer Res. 53:1993;1322.
3. Langman M.J., Cheng K.K., Gilman E.A., Lancashire R.J. Effect of anti-inflammatory drugs on overall risk of common cancer Case-control study in general practice research database. B.M.J. 320:2000;1642.
4. Farrow D.C., Vaughan T.L., Hansten P.D., Stanford J.L., Risch H.A., Gammon M.D., Chow W.H., Dubrow R., Ahsan H., Mayne S.T., Schoenberg J.B., West A.B., Rotterdam H., Fraumeni J.F. Jr, Blot W.J. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 7:1998;97.
5. Schreinemachers D.M., Everson R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 5:1994;138.
6. Li M., Lotan R., Levin B., Tahara E., Lippman S.M., Xu X.C. Aspirin induction of apoptosis in esophageal cancer A potential for chemoprevention. Cancer Epidemiol. Biomarkers Prev. 9:2000;545.
7. Rubio C.A. Antitumoral activity of indomethacin on experimental esophageal tumors. J. Natl. Cancer Inst. 72:1984;705.
8. Rubio C.A. Further studies on the therapeutic effect of indomethacin on esophageal tumors. Cancer. 58:1986;1029.
9. Kerins D.M., Murray R., FitzGerald G.A. Prostacyclin and prostaglandin E1 Molecular mechanisms and therapeutic utility. Prog. Hemost. Thromb. 10:1991;307.
10. Kujubu D.A., Fletcher B.S., Varnum B.C., Lim R.W., Herschman H.R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266:1991;12866.
11. DuBois R.N., Awad J., Morrow J., Roberts L.J. 2nd, Bishop P.R. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J. Clin. Invest. 93:1994;493.
12. Jones D.A., Carlton D.P., McIntyre T.M., Zimmerman G.A., Prescott S.M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem. 268:1993;9049.
13. Rimarachin J.A., Jacobson J.A., Szabo P., Maclouf J., Creminon C., Weksler B.B. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler. Thromb. 14:1994;1021.
14. Mestre J.R., Subbaramaiah K., Sacks P.G., Schantz S.P., Tanabe T., Inoue H., Dannenberg A.J. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res. 57:1997;2890.
15. Mestre J.R., Subbaramaiah K., Sacks P.G., Schantz S.P., Tanabe T., Inoue H., Dannenberg A.J. Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2. Cancer Res. 57:1997;1081.
16. Subbaramaiah K., Altorki N., Chung W.J., Mestre J.R., Sampat A., Dannenberg A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 274:1999;10911.
17. Biramijamal F., Allameh A., Mirbod P., Groene H.J., Koomagi R., Hollstein M. Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran. Cancer Res. 61:2001;3119.
18. Kelley D.J., Mestre J.R., Subbaramaiah K., Sacks P.G., Schantz S.P., Tanabe T., Inoue H., Ramonetti J.T., Dannenberg A.J. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis. 18:1997;795.
19. Zhang F., Subbaramaiah K., Altorki N., Dannenberg A.J. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J. Biol. Chem. 273:1998;2424.
20. Zhang F., Altorki N.K., Wu Y.C., Soslow R.A., Subbaramaiah K., Dannenberg A.J. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats Evidence for involvement of bile acids. Gastroenterology. 121:2001;1391.
21. Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E., Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59:1999;198.
22. Wilson K.T., Fu S., Ramanujam K.S., Meltzer S.J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 58:1998;2929.
23. Ristimaki A., Honkanen N., Jankala H., Sipponen P., Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1997;1276.
24. Kaur B.S., Khamnehei N., Iravani M., Namburu S.S., Lin O., Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology. 123:2002;60.
25. Shamma A., Yamamoto H., Doki Y., Okami J., Kondo M., Fujiwara Y., Yano M., Inoue M., Matsuura N., Shiozaki H., Monden M. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin. Cancer Res. 6:2000;1229.
26. Shirvani V.N., Ouatu-Lascar R., Kaur B.S., Omary M.B., Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma Ex vivo induction by bile salts and acid exposure. Gastroenterology. 118:2000;487.
27. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803.
28. Liu C.H., Chang S.H., Narko K., Trifan O.C., Wu M.T., Smith E., Haudenschild C., Lane T.F., Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276:2001;18563.
29. Marnett L.J., Reed G.A., Dennison D.J. Prostaglandin synthetase- dependent activation of 7,8-dihydro-7,8-dihydroxy-geno (a) pyrene to mutagenic derivatives. Biochem. Biophys. Res. Commun. 82:1978;210.
30. Eling T.E., Thompson D.C., Foureman G.L., Curtis J.F., Hughes M.F. Prostaglandin H synthase and xenobiotic oxidation. Annu. Rev. Pharmacol. Toxicol. 30:1990;1.
31. Liu X.H., Yao S., Kirschenbaum A., Levine A.C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 58:1998;4245.
32. Souza R.F., Shewmake K., Beer D.G., Cryer B., Spechler S.J. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 60:2000;5767.
33. Li M., Wu X., Xu X.C. Induction of apoptosis by cyclooxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells. Int. J. Cancer. 93:2001;218.
34. Weitzman S.A., Gordon L.I. Inflammation and cancer Role of phagocyte-generated oxidants in carcinogenesis. Blood. 76:1990;655.
35. Chang-Claude J.C., Wahrendorf J., Liang Q.S., Rei Y.G., Munoz N., Crespi M., Raedsch R., Thurnham D.I., Correa P. An epidemiological study of precursor lesions of esophageal cancer among young persons in a high-risk population in Huixian, China. Cancer Res. 50:1990;2268.
36. Crespi M., Munoz N., Grassi A., Qiong S., Jing W.K., Jien L.J. Precursor lesions of oesophageal cancer in a low-risk population in China Comparison with high-risk populations. Int. J. Cancer. 34:1984;599.
37. Lagergren J., Bergstrom R., Lindgren A., Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340:1999;825.
38. Hameeteman W., Tytgat G.N., Houthoff H.J., van den Tweel J.G. Barrett's esophagus Development of dysplasia and adenocarcinoma. Gastroenterology. 96:1989;1249.
39. Oberg S., Peters J.H., DeMeester T.R., Lord R.V., Johansson J., DeMeester S.R., Hagen J.A. Determinants of intestinal metaplasia within the columnar-lined esophagus. Arch. Surg. 135:2000;651.
40. Oberg S., Ritter M.P., Crookes P.F., Fein M., Mason R.J., Gadensytatter M., Brenner C.G., Peters J.H., DeMeester T.R. Gastroesophageal reflux disease and mucosal injury with emphasis on short-segment Barrett's esophagus and duodenogastroesophageal reflux. J. Gastrointest. Surg. 2:1998;547.
41. Plescia O.J., Smith A.H., Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc. Natl. Acad. Sci. U.S.A. 72:1975;1848.
42. Brunda M.J., Herberman R.B., Holden H.T. Inhibition of murine natural killer cell activity by prostaglandins. J. Immunol. 124:1980;2682.
43. Taffet S.M., Russell S.W. Macrophage-mediated tumor cell killing Regulation of expression of cytolytic activity by prostaglandin E. J. Immunol. 126:1981;424.
44. Baker P.E., Fahey J.V., Munck A. Prostaglandin inhibition of T-cell proliferation is mediated at two levels. Cell Immunol. 61:1981;52.
45. Kunkel S.L., Wiggins R.C., Chensue S.W., Larrick J. Regulation of macrophage tumor necrosis factor production by prostaglandin E2. Biochem. Biophys. Res. Commun. 137:1986;404.
46. Kambayashi T., Alexander H.R., Fong M., Strassmann G. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J. Immunol. 154:1995;3383.
47. Stolina M., Sharma S., Lin Y., Dohadwala M., Gardner B., Luo J., Zhu L., Kronenberg M., Miller P.W., Portanova J., Lee J.C., Dubinett S.M. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164:2000;361.
48. Gallo O., Franchi A., Magnelli L., Sardi I., Vannacci A., Boddi V., Chiarugi V., Masini E. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia. 3:2001;53.
49. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cel. 93:1998;705.
50. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306.
51. Williams C.S., Tsujii M., Reese J., Dey S.K., DuBois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105:2000;1589.
52. Carbone D., Choy H., Csiki I., Dang T., Campbell N., Garcia B., Morrow J., Saha D., Johnson D.H., Sandler A. Serum/plasma VEGF level changes with cyclooxygenase-2 (COX-2) inhibition in combined modality therapy in stage III non-small cell lung cancer (NSCLC) Prelimnary results of a phase II trial (THO-0059). 2002;. 38th Annual Meeting of the American Society of Clinical Oncology 38th annual meeting, May 18-21. Orlando, FL, Abstract.
53. Tsujii M., Kawano S., DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3336.
54. Dohadwala M., Luo J., Zhu L., Lin Y., Dougherty G.J., Sharma S., Huang M., Pold M., Batra R.K., Dubinett S.M. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J. Biol. Chem. 276:2001;20809.
55. Tomozawa S., Nagawa H., Tsuno N., Hatano K., Osada T., Kitayama J., Sunami E., Nita M.E., Ishihara S., Yano H., Tsuruo T., Shibata Y., Muto T. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br. J. Cancer. 81:1999;1274.
56. Kawamori T., Rao C.V., Seibert K., Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409.
57. Li Z., Shimada Y., Kawabe A., Sato F., Maeda M., Komoto I., Hong T., Ding Y., Kaganoi J., Imamura M. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis. 22:2001;547.
58. Buttar N.S., Wang K.K., Leontovich O., Westcott J.Y., Pacifico R.J., Anderson M.A., Krishnadath K.K., Lutzke L.S., Burgart L.J. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology. 122:2002;1101.
59. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342:2000;1946.
60. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Gunawan E.S., Takei Y., Nagano K., Hori M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol. 274:1998;G1061.
61. Moore R.J., Zweifel B.S., Heuvelman D.M., Leahy K.M., Edwards D.A., Woerner B.M., Ornberg R.L., Seibert K., Koki A.T., Masferrer J.L. Enhanced antitumor activity by co-administration of celecoxib and the chemotherapheutic agents cyclophosphamide and 5-FU. Proc. Am. Assoc. Cancer Res. 41:2000;409.
62. Milas L., Kishi K., Hunter N., Mason K., Masferrer J.L., Tofilon P.J. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst. 91:1999;1501.
63. Enzinger P.C.H.M., Bueno R., Choi N., Fidias P., Kulke M., Sugarbaker D., Wright C., Donahue D., Lynch T. Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. Proc. Am. Soc. Clin. Oncol. 22:2003;361.
64. Mantravadi R.V.P., Fineberg N., Ansari R., Fox E., Helft P., Kesler K., Hanna N., Einhorn L.H., Stoner C., Govindan R. A phase II study of csiplatin, 5-fluorouracil (5-FU), radiation (RT) and celecoxib in patients with resectable esophageal cancer (EC) Preliminary results from the Hoosier Oncology Group (HOG). Proc. Am. Soc. Clin. Oncol. 22:2003;291.